Teva Pharmaceutical Industries (TEVA) to Release Quarterly Earnings on Wednesday

Teva Pharmaceutical Industries (NYSE:TEVA) is scheduled to release its earnings data before the market opens on Wednesday, May 8th. Analysts expect Teva Pharmaceutical Industries to post earnings of $0.49 per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Teva Pharmaceutical Industries Trading Down 0.7 %

Shares of TEVA stock opened at $13.98 on Monday. The company has a market cap of $15.67 billion, a P/E ratio of -29.74, a PEG ratio of 1.67 and a beta of 1.04. Teva Pharmaceutical Industries has a fifty-two week low of $7.09 and a fifty-two week high of $14.47. The stock has a 50 day simple moving average of $13.61 and a two-hundred day simple moving average of $11.61. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02.

Insider Activity

In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 100,000 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the transaction, the executive vice president now directly owns 382,590 shares in the company, valued at approximately $5,172,616.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 100,000 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total value of $1,352,000.00. Following the completion of the sale, the executive vice president now directly owns 382,590 shares of the company’s stock, valued at approximately $5,172,616.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Eric Drape sold 173,261 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the transaction, the vice president now directly owns 1 shares in the company, valued at approximately $13.05. The disclosure for this sale can be found here. Insiders have sold 358,972 shares of company stock worth $4,739,820 over the last 90 days. 0.55% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Jefferies Financial Group upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and boosted their target price for the company from $10.00 to $14.00 in a research report on Tuesday, January 23rd. Barclays raised their target price on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Monday, February 5th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price for the company in a research report on Friday, March 8th. Piper Sandler upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $12.00 to $19.00 in a report on Monday, February 12th. Finally, The Goldman Sachs Group boosted their price objective on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Monday, February 5th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $13.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.